



## TriSalus Life Sciences to Showcase Treatment Platform and Present Pressure-Enabled Regional Immuno-Oncology (PERIO) Data at the Society of Interventional Radiology's 2023 Annual Scientific Meeting

February 28, 2023 5:00 PM EST

\*\*\* MEDIA ADVISORY \*\*\*

**PHOENIX, February 28, 2023** – [TriSalus Life Sciences@ Inc.](#) ("TriSalus" or the "company"), an oncology company integrating immunotherapy with disruptive delivery technology to transform the treatment paradigm for patients with liver and pancreatic tumors, will participate in a series of events at the [Society of Interventional Radiology \(SIR\) 2023 Annual Scientific Meeting](#), held March 4-9, 2023, at the Phoenix Convention Center.

At this year's conference, new data from Phase 1/1b of the company's [Pressure-Enabled Regional Immuno-Oncology \(PERIO\)](#) clinical trial program will be presented. The PERIO-01 and PERIO-02 trials are studying an investigational toll-like receptor 9 agonist, [SD-101](#), delivered intravascularly by the [TriNav® Infusion System](#) ("TriNav®") using the company's proprietary [Pressure-Enabled Drug Delivery™ \(PEDD™\)](#) method of administration. The studies are evaluating whether this platform approach can improve the performance of systemic checkpoint inhibitors in treating patients with uveal melanoma with liver metastases, hepatocellular carcinoma or intrahepatic cholangiocarcinoma.

In addition to several data presentations, the company is hosting numerous educational opportunities for interventional radiologists to learn more about the company's FDA-cleared TriNav® Infusion System, including multiple in-booth presentations, a lunch symposium and an evening networking reception. The TriNav® Infusion System utilizes the PEDD™ method of administration with SmartValve™ technology to overcome intratumoral pressure and improve delivery of therapeutic agents during outpatient interventional radiology procedures.

The details of these additional activities are highlighted below. Oral abstract presentations listed below are part of the SIR 2023 CME-accredited scientific program and are *not* TriSalus-sponsored activities.

### ON-SITE TRISALUS SPOKESPERSONS

Mary Szela, MBA, CEO and President  
Steven C. Katz, MD, FACS, Chief Medical Officer  
Jennifer L. Stevens, JD, Chief Regulatory Officer  
Bryan F. Cox, PhD, Chief of Research  
David B. Jaroch, PhD, Senior Principal Scientist  
Alexander Y. Kim, MD, Consultant, Director of Interventional Oncology Clinical Strategies

### CONFERENCE ACTIVITIES

Sunday, March 5 – Wednesday, March 8

**TriNav® Exhibition; Location: Exhibit Hall, Booth #1023**

Visit Booth #1023 to learn more about the TriNav® Infusion System and its ability to improve tumor response and enhance therapeutic delivery.

Two in-booth presentations, led by practicing interventional radiologists, will also be taking place:

- **The Tumor Microenvironment – Understanding the Barriers to Effective Treatment (March 5, 2:30pm-3:00pm MST)**
  - Ripal Gandhi, MD, Miami Cardiac and Vascular Institute and Miami Cancer Institute
- **The Benefits of PEDD™ – Real World Experience with TriNav® (March 6, 10:00am-10:30am MST)**
  - A. Michael Devane, MD, FSIR, Prisma Health Upstate/University of South Carolina School of Medicine Greenville

Sunday, March 5

**SIR Foundation Research Gala, 6:30pm-10:30pm MST; Location: Scottsdale Resort at McCormick Ranch**

TriSalus is proud to be a bronze sponsor of the SIR Foundation's annual gala, a premier fundraising event focused on advancing research progress in interventional radiology.

Monday, March 6

**Oral Abstract Presentation, 3:00pm-3:09pm MST; Location: Room 227ABC**

**Abstract Title: The Effects of a Pressure-Enabled Drug Delivery™ Microcatheter on Radiotracer Distribution Compared to a Standard**

## **Microcatheter in Radioembolization, an Interim Analysis**

Learn more from TriSalus research collaborators at Massachusetts General Hospital about differences in delivery between the Pressure-Enabled Drug Delivery™ (PEDD™) microcatheter and a standard microcatheter in pre-radioembolization mapping procedures.

**Oral Abstract Presentation, 4:12pm-4:21pm MST; Location: Room 225AB**

### **Abstract Title: Hepatic Arterial Infusion of the Class C TLR9 Agonist SD-101 in Pressure Enabled Regional Immuno-Oncology (PERIO) Phase 1/1b Trials for Liver Tumors**

The PERIO-01 and PERIO-02 clinical trials are studying investigational SD-101 delivered by the PEDD™ method of administration in uveal melanoma with liver metastases, advanced hepatocellular carcinoma, and advanced intrahepatic cholangiocarcinoma. Hear Rahul Sheth, MD, Associate Professor of Interventional Radiology, MD Anderson Cancer Center, discuss data from the trials, co-authored by TriSalus colleagues Bryan Cox, PhD, Steven Katz, MD, Ann-Marie Hulstine, and Zoe Nguyen.

**Hands-on Workshop – Interventional Oncology: Embolization, 8:30am-10:00am MST; Location: Expo Halls 4-5**

During this interactive workshop, attendees will have the opportunity to understand the unique features of the TriNav® Infusion System that distinguish it from conventional delivery methods.

Tuesday, March 7

**Lunch Symposium with TriSalus Life Sciences®, 12:00pm-1:00pm MST; Location: Room 128AB**

Alex Kim, MD; Resmi A. Charalel, MD, MPH, Assistant Professor of Radiology and Population Health Sciences at Weill Cornell Medicine; and David Jaroch, PhD, will discuss current evidence for PEDD™. The symposium will discuss intratumoral pressure and vascular resistance and include a review of PEDD™ data featuring case studies.

**Educational Interactive Symposium with TriSalus Life Sciences®, 6:00pm-8:00pm MST; Location: Sheraton Phoenix Downtown, Room: Valley of the Sun D**

Join TriSalus for an interactive exchange including two demonstrations on drug delivery barriers and the Pressure-Enabled Drug Delivery™ (PEDD™) approach. (Media can RSVP for this event by emailing [press@trisaluslifesci.com](mailto:press@trisaluslifesci.com)).

Wednesday, March 8

**Oral Abstract Presentation, 3:36pm-3:45pm MST; Location: Room 222AB**

### **Abstract Title: Pancreatic Retrograde Venous Infusion (PRVI™) Significantly Enhances Delivery of NearIR Labelled SD-101 TLR9 Agonist to Targeted Regions of the Porcine Pancreas**

David Jaroch, PhD, will discuss pre-clinical data from a study examining Pancreatic Retrograde Venous Infusion (PRVI™), a trans-venous approach for the regional treatment of pancreatic tumors, using investigational drug SD-101. Co-authors of the study include Steven Katz, MD, and Bryan Cox, PhD.

**Oral Abstract Presentation, 4:21pm-4:30pm MST; Location: Room 222AB**

### **Abstract Title: Pancreatic Venous Anatomy for Trans-portal Treatment of Pancreatic Cancers Using Pressure-Enabled Drug Delivery™ (PEDD™)**

Michael Kwong, BA, medical student at the University of Colorado Anschutz Medical Campus, will be presenting clinical data to inform the use of the PEDD™ method in treating pancreatic cancers.

###

## **About TriSalus**

TriSalus is an oncology company integrating immunotherapy with disruptive delivery technology to transform the treatment paradigm for patients with liver and pancreatic tumors. TriSalus' proprietary platform approach addresses immune dysfunction in liver and pancreatic tumors by combining its highly effective drug delivery technology with immunotherapeutics. The TriSalus platform comprises the TriNav® Infusion System and SD-101, a class C toll-like receptor 9 ("TLR9") agonist. TriNav® is an FDA-cleared device that is designed to administer established and emerging therapeutics. SD-101, the company's investigational TLR9 agonist, is being delivered via TriNav® to selected sites, including tumors in the liver. TriNav® is the latest TriSalus asset for the proprietary PEDD™ method of administration which has been shown to overcome intratumoral pressure through modulation of pressure and flow to increase delivery of therapeutic agents.

## **For Patients**

To learn more about clinical trial treatment protocol and enrollment, visit <http://www.periotrial.com> or <http://www.clinicaltrials.gov> and search NCT04935229 or NCT05220722.

## **Media Contact**

[press@trisaluslifesci.com](mailto:press@trisaluslifesci.com)